Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
François Raffi, Anton Pozniak, Elizabeth C. George(MRC Clinical Trials Unit at UCL), Remko van Leeuwen(Amsterdam Institute for Global Health and Development), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), José Ramón Arribas(Hospital Universitario La Paz), Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Juliette Saillard(Agence Nationale de Recherches sur le Sida et les Hépatites Virales), Fleur Hudson(Royal Free London NHS Foundation Trust), Per O Jansson(University of Copenhagen), Stefano Vella, Geneviève Chêne(Bordeaux Population Health), Jesper Grarup(University of Copenhagen), Abdel G. Babiker(MRC Clinical Trials Unit at UCL), Christine Schwimmer(Université de Bordeaux), Jean-François Delfraissy(Agence Nationale de Recherches sur le Sida et les Hépatites Virales), Clotilde Allavena(Centre Hospitalier Universitaire de Nantes), Cédrick Wallet(Université de Bordeaux), Laura Richert(Université de Bordeaux)
Cited by 175
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Antiretroviral Therapy for HIV Infection in 1998
|JAMA|1998|1k